Aktieanalys

Optomed: Initial take on Q4 2022 results - Redeye

Redeye Publicerad: 17 Feb 2023 09:11

Redeye provides an initial take on Optomed’s Q4 2022 report. The year has been in line with our expectations, with total sales of EUR14.7m (EUR14.9m), which can be compared to our sales estimate of EUR14.5m. We are positive the sales were at the same level as in 2021 due to the uncertainties in China, which has clearly affected the company. We will provide an update shortly; however, as our estimates for the year were close to spot on, and our view of 2023 remains the same, we do not expect to make any major changes in our estimates for the following years and look forward to an eventful 2023.

Länk till analysen i sin helhet: https://www.redeye.se/research/879705/optomed-initial-take-on-q4-2022-results?utm_source=finwire&utm_medium=RSS

Nyheter om Optomed

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!